Kymera Therapeutics Inc (KYMR) News

Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy

WATERTOWN, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a...

Form 4 - Statement of changes in beneficial ownership of securities

Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting

KT-333 demonstrated initial clinical proof of concept across multiple hematological malignancies, including...

Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting

KT-253 demonstrates initial clinical proof of concept in patients with tumor types shown to be sensitive in...

Kymera Therapeutics to Participate in Upcoming June Investor Conferences

WATERTOWN, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage...

Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting

Abstract released today highlights safety, pharmacodynamic and clinical response data with additional data to...

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting

KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in...

Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting

Abstract released today highlights safety, pharmacodynamic and clinical response data collected through...

Kymera Therapeutics to Participate in Upcoming May Investor Conferences

WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage...

Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update

KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of...

Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2

WATERTOWN, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a...

Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting

New preclinical data on novel E3 pairing and structural mechanisms for KT-333, a First-in-Class STAT3 degrader...

Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting

KT-621 (STAT6) and KT-294 (TYK2) have the potential to provide biologics-like activity with oral small molecule...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities